construct (Drli55::Empty) could not prevent expression of the eut genes in ethanolamine alone (as in the parental Drli55 strain), whereas a strain with a wild-type copy of rli55 (Drli55::rli55) fully restored Rli55-mediated inhibition. However, a strain with a deletion in the riboswitch (Drli55::Dribo) inhibited eut expression in all conditions, as the riboswitch can no longer terminate rli55 transcription in response to B 12 . In strain Drli55::rli55DM1, wherein four uridine residues in the first ANTAR site were mutated to adenines (Fig. 3D, DM1) , inhibition of eut expression by Rli55 was abolished in the presence of ethanolamine alone. In contrast, in strain Drli55::rli55DM1/M2, where compensatory mutations were made to the opposite side of the ANTAR stem-loop (Fig. 3D, DM2) , wild-type regulation of eut expression was restored. Mutation of the six nucleotides in the stem-loop of the second ANTAR element (Fig. 3D , DM3, Drli55::rli55DM3) had no significant effect on Rli55-mediated regulation. Thus, the first ANTAR element is necessary and sufficient for Rli55-mediated regulation.
The long form of Rli55 containing an ANTAR element might bind and sequester EutV and so prevent it from activating expression of the eut genes in the presence of ethanolamine but absence of B 12 . When sufficient levels of B 12 accumulate, B 12 would bind the riboswitch, producing truncated Rli55 transcripts, which would lack an ANTAR element and be unable to sequester EutV. To examine this hypothesis, we constructed a strain with an additional copy of the eutV gene carrying a 2XFLAG-tag (EutV FLAG   ) and first showed that expression of EutV FLAG protein is regulated identically to the native eutV gene in response to ethanolamine and B 12 ( fig. S6A ). We also constructed a strain with an additional eutV gene lacking a FLAG tag (EutV NOFLAG ). Anti-FLAG immunoprecipitations of cell lysates from these two strains ( fig. S6 , B and C), followed by RNA-seq analysis (Fig. 3 , E and F), showed that Rli55 is enriched by coimmunoprecipitation with EutV FLAG primarily when bacteria are grown in the presence of ethanolamine alone, although we saw no enrichment in a parallel immunoprecipitation with the EutV NOFLAG strain (Fig. 3E ). In contrast, the ANTAR element upstream of the eutV gene ( Fig. 3F ) is enriched by coimmunoprecipitation of lysates from EutV FLAG bacteria, but not EutV NOFLAG bacteria, grown in the presence of ethanolamine and B 12 together but not from lysates of bacteria grown in ethanolamine alone. To a lesser extent, the ANTAR-containing region upstream of eutA and the entire eutA-Q locus are enriched under the latter condition ( fig. S7 ). These data support a model in which the majority of EutV is bound and sequestered by Rli55 in the presence of ethanolamine alone. Conversely, in the presence of ethanolamine and B 12 , the riboswitch produces short truncated Rli55 transcripts, which cannot bind EutV, and so allows EutV to bind eut mRNAs and to activate eut expression (Fig. 3G) .
This riboregulatory mechanism coordinates expression of the ethanolamine utilization (eut) locus with the availability of B 12 , the essential cofactor for ethanolamine catabolism. Previously, ethanolamine utilization has been shown to be important after oral infection by Salmonella enterica serovar Typhimurium and enterohemorrhagic Escherichia coli (3, 4, 14) ; however, the contribution of ethanolamine utilization to L. monocytogenes pathogenesis in an intravenous mouse infection model suggests that ethanolamine utilization is important outside of the intestine and possibly in the intracellular environment. This study also extends the role of riboswitches in the regulation of noncoding RNAs (15, 16) . Finally, our data show that Rli55 represents a new member of the small family of regulatory RNAs that function by sequestering a protein, which also includes the 6S and CsrB/C RNAs (17) , and highlights a distinctive means of signal integration in bacterial gene regulation.
IMMUNOGENETICS

Chromatin state dynamics during blood formation
David Lara-Astiaso, (3) (4) (5) (6) (7) . Resolving this discrepancy requires observation of chromatin dynamics during intermediate stages of differentiation.
An important model system for differentiation is hematopoiesis, in which a single hematopoietic stem cell gives rise to a large number of cell types (comprising the blood) through a series of characterized intermediate progenitor cells (8, 9) . Chromatin regulation has a central role in hematopoiesis: Mutations or loss of chromatin factors lead to hematopoiesis defects and diseases (10) . Moreover, genome-wide chromatin profiling studies have revealed large-scale differences in the histone modifications and transcription factor binding maps between mature immune cell types (3) (4) (5) (6) 11) . Thus, dramatic chromatin reorganizations during hematopoiesis are critical for early hematopoietic decisions (12) .
Comprehensive study of the chromatin events during hematopoiesis has been hampered by the low sensitivity and reproducibility for small cell numbers with current chromatin immunoprecipitation (ChIP) protocols. These protocols require several enzymatic steps with limited performance when the input DNA is below the nanogram range. Whereas an average diploid mammalian cell has roughly 4 to 8 pg of DNA, losses after ChIP reduce the available DNA for analysis by 2 to 3 orders of magnitude, setting the lower limit for genome-wide chromatin analysis at 50,000 cells (13) . Amplification of ChIP material partially alleviates this problem at the cost of introducing amplification biases (14, 15) .
To profile chromatin dynamics of scarce in vivo cell populations, we developed an indexing-first chromatin IP approach (iChIP). In this protocol, barcoding is performed directly on the total cellular chromatin (Fig. 1A) , thereby avoiding the low-input enzymatic reactions occurring in conventional ChIP. Importantly, this enables multiple chromatin-barcoded samples to be pooled for ChIP in the same well, further reducing initial input requirements and increasing cross-sample reproducibility. To minimize centrifugation steps, cells are fixed before sorting and sonication. Then, the sheared chromatin is immobilized on magnetic beads coated with antibody to H3 and then indexed. The indexed chromatin is released from the H3 beads and pooled with chromatin from other samples. Finally, ChIP is performed with the desired antibody, and a single chromatin-barcoded pool can be divided among multiple ChIPs for profiling various chromatin modifications.
The iChIP protocol is highly reproducible for low cell numbers (a few hundred cells) while increasing the sensitivity and throughput (Fig. 1) . To benchmark iChIP, we barcoded decreasing amounts (10,000 to 500 cells) of chromatin isolated from bone-marrow-derived dendritic cells (BMDCs), in triplicate, and performed ChIP on the barcoded chromatin with an antibody to mono-and trimethylated histone H3 lysine 4 (H3K4me1 and H3K4me3) ( Fig. 1 , B to D, and fig. S1 ). We confirmed reproducibility of H3K4me3 peaks between replicates of 10,000 cells (r = 0.95) down to 500 cells (r = 0.85). iChIP profiles correlated with conventional ChIP-seq on 10 million BMDCs (r = 0.92) (16) . iChIP is applicable to profile other histone modifications and transcription factors for low cell numbers (Fig. 1, C and D,  and fig. S1 ). The reproducibility and sensitivity for small cell numbers of iChIP open the way for in vivo characterization of chromatin dynamics during hematopoiesis.
We profiled four histone modifications (H3K4me1, H3K4me2, H3K4me3, and H3K27ac) (17) in three in vivo replicates at 16 developmental stages of hematopoietic commitment using 5000 cells per mark. The cell populations chosen comprise all multipotent progenitor stages and the common lineage oligopotent progenitors from each of the major blood lineages (myeloid, lymphoid, and erythroid), as well as several terminally differentiated cell types from each of the lineages (https://www.immgen.org) (16) (Fig. 2A) .
Replicates of histone modifications ChIP and RNA-seq displayed high reproducibility [average r = 0.95 (16)] (fig. S2 and tables S1 and 2). We used histone marks to define promoter (high H3K4me3) and enhancer (high H3K4me1/2 and low H3K4me3) regions, resulting in analysis of 48,415 enhancers and 17,923 promoters (16) . Enhancer activity was defined from H3K27ac levels and RNA expression values of the nearest gene (16) (17) (18) . Genomewide analysis of RNA expression and promoter activity (H3K4me3 signal) identified four major patterns for progenitor, lymphoid, myeloid, and erythroid cells (Fig. 2B and figs. S2 and S3). In contrast, H3K4me1 signal revealed that lineage progenitors were more similar to the differentiated cells within their lineage than to progenitors from other cell lineages (Fig. 2B and figs. S2 and S3). This distinction suggests that enhancer establishment is initiated in early lineage commitment and can reveal the differentiation potential of progeny before the execution of the RNA expression program.
Changes in chromatin marks during hematopoiesis (particularly H3K4me1 and H3K4me2) suggest lineage-specific activity of regulatory elements. Of the 48,415 hematopoietic enhancers, 90% (43,428) changed state during hematopoiesis (16) . We found that 60% (26,393) of these dynamic enhancers show the stereotypical behavior in which they are initially marked in hematopoietic stem cells (HSCs) but are maintained only in the relevant lineage [ Fig. 2C (Gata2) and fig. S4A (Meis1 and CD34)] . Surprisingly, we discovered that a large proportion of dynamic enhancers (40%, 17,035) are established de novo during the differentiation process (16) . For example, enhancers present in myeloid gene loci IL-1b, CD14, S100a8, and F7 (coagulation factor VII) are either established de novo or become more prominent in the myeloid lineage (Fig. 2C and fig. S4A ). Similarly, Ebf1 and Cr2 enhancers are established in B cells; Bcl11b and CD3g enhancers in T cells; Granzyme A and Ncr1 enhancers in natural killer cells (NK) cells; and Gata1, Gypa (glycophorin A), and Cpox (coproporphyrinogen oxidase) enhancers in the erythroid lineage (Fig. 2 and figs. S3B and S4A) .
The establishment of de novo lineage-specific enhancers occurs mainly at the root of the commitment point in the first progenitor of the lineage, whereas closing of enhancers occurs more gradually (Fig. 2) . For example, S100a8, F7 and F10 loci display H3K4me1 signal specifically in the myeloid lineage, with de novo establishment of the enhancers at the root of the myeloid commitment point in common myeloid progenitor (CMP) (Fig. 2C and figs. S3B and S4A) . Similarly, the Cpox and Gypa loci display H3K4me1 signal specifically in the erythrocyte lineage, with de novo establishment of the enhancers at the root of the erythrocyte commitment point in the megakaryocyte erythroid progenitor (MEP) (Fig. 2C) . Importantly, we observe a stepwise acquisition of the different chromatin modifications in the lineage-specific enhancers during hematopoiesis ( Fig. 2D and figs. S4B and S5). For example, in both S100a8 (myeloid lineage) and Gypa (erythroid lineage) loci, H3K4me1/2 appear first in the root lineage progenitor (CMP and MEP, respectively), whereas H3K27ac (locus activation) is acquired together with active RNA transcription only once the cells (granulocytes and erythrocyte B) are terminally differentiated (Fig. 2D and  fig. S4B ). Globally, 32% of the activated (H3K27ac) enhancers in terminally differentiated cells are initially poised (H3Kme1 only) in the lineage progenitors (16) .
Clustering of all 48,415 H3K4me1 peaks by their dynamic profiles during hematopoiesis revealed nine major clusters, consistent with the underlying biology of the system (Fig. 3A and  fig. S6, A and B) (16) . H3K4me2 signal shows similar patterns in all nine clusters ( fig. S6A ). Cluster I comprises enhancers shared throughout hematopoiesis. Clusters II to IV group lineagespecific enhancers already marked in HSCs and shared with hematopoietic progenitors. Finally, clusters VI (Fig. 3B, middle) , VII, VIII, and IX (Fig. 3B, bottom) group de novo enhancers that are specific to a particular lineage and were not marked in HSCs with 6382 myeloid, 5834 lymphoid, and 4819 erythroid enhancers. We also found a group of 6612 enhancers (cluster V) shared exclusively among progenitors (Fig. 3B, top) . Interestingly, the erythrocyte and progenitor enhancer clusters exhibit relatively high sequence conservation (16) in the mammalian clade, with the myeloid and lymphoid enhancers displaying lower conservation. These data suggest differential rates of evolutionary dynamics in these cis-regulatory regions (16) (Fig. 3A) .
Newly formed enhancers could either be established at a specific branching point or established gradually during the development process. To further examine these dynamics, we generated a catalog of enhancers that are dynamic (gained or lost) during the process of differentiation from the long-term hematopoietic stem cells (LT-HSCs) to mature, terminally differentiated cells (Fig.  3C) . We determined, for each enhancer, the stage of gain or loss along the differentiation path. In erythroid differentiation, 65% of the de novo enhancer repertoire are gained in the MEP stage (Fig. 3D) . Similarly, 40 to 50% of the de novo myeloid enhancers are gained in the first step of myeloid commitment, during the multipotent progenitor (MPP) to CMP transition, whereas the CMP to GMP transition involves fewer gains (15 to 30%). Together, the CMP and GMP stages are responsible for 63 to 80% of gained enhancers in terminally differentiated myeloid cells (Fig. 3D) enhancer similarity of CMP and GMP with the myeloid lineage (Fig. 2B) . In contrast, enhancer loss is a more gradual process that initiates in the CMP or MEP stage (for myeloid and erythrocyte development, respectively) with a large proportion (40 to 50%) of enhancers lost in the last and definitive differentiation step to mature cells ( fig. S6C) .
Genome-wide studies show that, whereas H3K4me1 marks both poised and active enhancers, H3K27ac marks only active enhancers (19, 20) . Because poised enhancers represent potential gene expression programs, the ratio of these enhancers in a given cell type approximates the current regulatory potential of the cell (20) . Analysis of the regulatory potential in hematopoiesis shows that progenitor cells are more plastic than differentiated cell types, with erythrocytes using most (78%) of their enhancers, whereas CMPs use only 33% of their enhancer potential (Fig. 3, E and F, and fig. S6D ) (16) . Within the progenitor group, CMP and GMP are more plastic than the multipotent stem cells (33 to 37% versus 62 to 65% of enhancer use), likely due to the de novo expansion of myeloid enhancers ( Fig. 2B and Fig. 3, A and F) . Notably, there is a wide spectrum of plasticity across the terminally differentiated cells, with the myeloid lineage (macrophages, monocytes, and granulocytes) showing higher degrees of plasticity than erythrocytes, B cells, and NK cells; this is consistent with the higher functional versatility of myeloid cells in comparison with other hematopoietic cell types (21) .
De novo H3K4me1 establishment in hematopoiesis is concomitant to an increase in chromatin accessibility (Fig. 4, A and B) . We measured chromatin accessibility, "open chromatin" (22) , during the developmental process in 10 hematopoietic cell types using the assay for transposaseaccessible chromatin followed by sequencing (ATAC-seq) (23) . In erythroid (Gypa) and myeloid (F7 and F10) gene loci, chromatin accessibility follows the temporal pattern observed for H3K4me1 (Fig. 4A) . As expected, the ATAC signal is enriched both in active promoters and H3K4me1-positive enhancers, as well as in insulators and other regulatory regions (23) . To evaluate the proportion of de novo enhancers that also display de novo establishment of open chromatin, we plotted the ATAC-seq signal in the regions from the H3K4me1 enhancer catalog ( fig. S7A) . We compared the ATAC-seq signal to H3K4me1 and H3K27ac intensities. We observed a similar pattern between ATAC and H3K4me1 signal (r = 0.75) and a weakened agreement with H3K27ac (r = 0.62) (Fig. 4B and fig. S7B ), suggesting that the process of gain or loss of H3K4me1 mark on enhancers occurs concomitantly with formation of open chromatin sites.
Establishment of lineage-specific enhancers is regulated by the activity of lineage-specific transcription factors (24) (Fig. 4, C to E) . Using the ATAC peaks (16) and our enhancer catalog, we searched for enriched transcription factor binding motifs in each cell type (Fig. 4C and  fig. S8 ) (16) to identify lineage-determining factors. We found that, in line with their identified functions, PU.1, Gata1, and Foxo1 can be classified as potential regulators of myeloid, erythroid, and lymphoid enhancers, respectively (3, 11, 25, 26) .
To systematically identify potential regulators, we generated a logistic regression model to predict enhancer activity at each stage from the DNA binding motif scores and transcription factor expression (Fig. 4, D and E, and figs. S8 to S11) (16) . Our logistic model accurately predicts enhancer cell-type-specific activity with 75% accuracy (with 70% sensitivity and 80% specificity) (fig. S10B) . Importantly, the model allowed us to elucidate the transcription factors controlling chromatin dynamics and lineage specification in hematopoiesis (25, 26) . Our model identified the known myeloid lineage determining factors PU.1, Cebpb, and Cebpa as regulators of myeloid enhancers; additionally, our model suggests a hierarchy between the Cebp factors, with Cebpa active in the progenitors (CMP/GMP) and Cebpb replacing Cebpa in the differentiated cell types (Fig. 4E and fig.  S11C ). Similarly, we identify Meis1, Hoxa9, and Erg as potential regulators of stem cell enhancers; Pax5 in B cells; Klf1 in erythroid cells; and Ets1 in lymphoid cells (Fig. 4, C to E, and fig. S11 ). We identify many transcription factors that have been implicated in lineage development but have not previously been associated with chromatin regulation of lineage determination, such as Irf1 and Irf2 in B cells and Cebpe in granulocytes (27, 28) . We also highlight new potential regulators of hematopoietic lineages: ATF3 in monocytes and Tcf7l2, Mef2a, and Runx2 in NK cells (Fig. 4E) . All together, our findings show that chromatin is highly dynamic during hematopoiesis, orchestrated by a defined set of transcription factors.
In conclusion, iChIP enables the execution of reproducible and sensitive ChIP on only a few hundred cells in a manner broadly applicable across organisms and tissues. We show that poised enhancers are established in lineage progenitors before their activation and precede RNA expression in subsequent lineage differentiation. These enhancers are established concomitantly with the formation of open chromatin sites. We then show that most of the enhancer dynamics can be accounted for by the activity of known lineage-specific factors as well as new candidate regulators. These results suggest a new model for chromatin dynamics during differentiation (Fig. 4F ) and show that development involves massive dynamic reorganization of the chromatin landscape. Whereas some enhancers are preset in hematopoietic stem cells, as suggested by the conventional development model, a comparable number of enhancers appear to be established de novo during hematopoiesis. We believe that the establishment of newly poised enhancers in the early lineage commitment steps initiates regulatory programs that are subsequently applied in differentiated cells, whereas the closing of enhancers occurs during later differentiation stages. This suggests that cellular enhancer potential reaches its maximum not at the HSC stage but during the oligopotent progenitor stages. Taken together, these observations reshape our understanding of the role of chromatin and pioneer factors during differentiation.
